CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Ontology highlight
ABSTRACT: BACKGROUND:The objective of this study was to investigate the expression and clinical role of 14 genes previously shown to be associated with chemotherapy response and/or progression-free survival in a smaller series of ovarian serous carcinoma effusions. METHODS:Advanced-stage serous ovarian carcinoma effusions (n?=?150) were analyzed for mRNA expression of AKR1C1, ABCA4, ABCA13, ABCB10, BIRC6, CASP9, CIAPIN1, FAS, MGMT, MUTYH, POLH, SRC, TBRKB and XPA using quantitative real-time PCR. mRNA expression was studied for association with clinicopathologic parameters, including chemotherapy response and survival. RESULTS:ABCA4 mRNA expression was significantly related to better (complete) chemotherapy response at diagnosis in the entire cohort (p?=?0.018), whereas higher POLH mRNA levels were significantly related to better chemoresponse at diagnosis in analysis to 58 patients with pre-chemotherapy effusions treated with standard chemotherapy (carboplatin?+?paclitaxel; p?=?0.023). In univariate survival analysis for patients with pre-chemotherapy effusions (n?=?77), CIAPIN1 mRNA expression was significantly related to shorter overall (p?=?0.007) and progression-free (p?=?0.038) survival, whereas ABCA13 mRNA expression was significantly related to shorter OS (p?=?0.024). Higher CIAPIN1 mRNA expression was an independent marker of poor overall survival in Cox multivariate analysis (p?=?0.044). CONCLUSIONS:Our data identify ABCA4 and POLH as markers of better chemotherapy response in metastatic serous carcinoma. CIAPIN1 and ABCA13 may be novel markers of poor outcome in pre-chemotherapy serous carcinoma effusions.
SUBMITTER: Nymoen DA
PROVIDER: S-EPMC4336750 | biostudies-literature | 2015 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA